ClinicalTrials.gg
CompletedNCT02949895Updated Aug 12, 2019

Study of BMS-986012 in Subjects With Small Cell Lung Caner

A Phase 1 interventional study of BMS-986012 and Cisplatin in Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
16th of 17
7 · median 92
Started
2016
with 2 others
Phase 1
6 of 19
none open now
Registered
11th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1, and was the 11th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

  • Histological or cytological confirmed small cell lung cancer (SCLC)
  • Performance Status 0-1
  • at least one that is not amenable to resection.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Symptomatic central nervous system (CNS)
  • Grade ≥ 2 peripheral neuropathy
  • Uncontrolled or significant cardiac disease
  • Active or chronic infection with (HIV), Virus (HBV), or Virus (HCV)

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Dose Escalation Dose 1

    BMS-986012 Dose Escalation Dose 1

    Drug: BMS-986012

  • Experimental
    Dose Escalation Dose 2

    BMS-986012 Dose Escalation Dose 2

    Drug: BMS-986012

  • Experimental
    Chemotherapy Combination

    BMS-986012 + Cisplatin + Etoposide

    Drug: BMS-986012 · Drug: Cisplatin · Drug: Etoposide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 2 years

  2. Number of participants with serious adverse events (SAEs )

    Time frame: Up to 2 years

  3. Number of Discontinuations due to AEs

    Time frame: Up to 2 years

  4. Number of Deaths due to AEs

    Time frame: Up to 2 years

  5. Number of participants with laboratory toxicity grade shift from baseline

    Time frame: Up to 2 years

Secondary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to 60 days after last dose

  2. Time of maximum observed serum concentration(Tmax)

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to 60 days after last dose

  3. Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T))

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to 60 days after last dose

  4. Observed serum concentration at the end of a dosing interval(Ctau)

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to 60 days after last dose

  5. Area under the concentration-time curve in 1 dosing interval(AUC(TAU))

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to 60 days after last dose

  6. Characterization of Immunogenicity as measured by Anti-Drug Antibodies (ADA)

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to 60 days after last dose

  7. Best overall response (BOR)

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to approximately 2 years

  8. Duration of response (DOR)

    Time frame: Cycle 1(each cycle is 21 days) Day 1 up to approximately 2 years

07

Study locations

2 sites
  • Local Institution
    Takatsuki-shi, Osaka 5698686, Japan
  • Local Institution
    Chuo-ku, Tokyo 1040045, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2017, 9 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 9 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Oct 31, 2016
StartActual
Nov 29, 2016
Primary completionActual
Aug 29, 2017
CompletionActual
Aug 29, 2017
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02949895
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Nov 29, 2016
Primary completion
Aug 29, 2017
Completion
Aug 29, 2017
Last update
Aug 12, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atigotatug

Start the discussion